Jinwon Life Sciences Subsidiary VGXI Participates in Bio USA

Jinwon Life Sciences announced on the 3rd that its subsidiary VGXI, a leading contract development and manufacturing organization (CDMO) in the nucleic acid biopharmaceutical field, will participate in the BIO International Convention (BIO USA) held in San Diego until the 6th (local time).

The company stated, "VGXI has recently expanded its sales force and is doing its best to secure orders based on its competitive high-quality plasmid DNA contract development and manufacturing capabilities," adding, "Through participation in this event, we will strive to achieve tangible results such as expanding partnerships by showcasing VGXI's excellent production capabilities and differentiated high-quality production services to potential clients."

Park Young-geun, CEO of Jinwon Life Sciences, said, "At this event, VGXI will have a great opportunity to contribute its expertise and technology by interacting with industry leaders and collaborating with next-generation therapeutic developers to innovatively improve gene medicines and provide better treatments to patients in need."

Bio USA is an annual event hosted by the Biotechnology Innovation Organization (BIO) in major U.S. cities with bio clusters. It is the largest international event in the biotechnology field, gathering more than 20,000 pharmaceutical and bio industry stakeholders worldwide to discuss investments and partnerships.

This content was produced with the assistance of AI translation services.